- Home
- AIM vs BREA Comparison
AIM vs BREA Comparison
Compare AIM & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- BREA
- Stock Information
- Founded
- AIM 1966
- BREA 2022
- Country
- AIM United States
- BREA Ireland
- Employees
- AIM N/A
- BREA N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- BREA Services-Misc. Amusement & Recreation
- Sector
- AIM Health Care
- BREA Consumer Discretionary
- Exchange
- AIM Nasdaq
- BREA Nasdaq
- Market Cap
- AIM 15.9M
- BREA 13.3M
- IPO Year
- AIM N/A
- BREA 2023
- Fundamental
- Price
- AIM $0.21
- BREA $0.80
- Analyst Decision
- AIM Strong Buy
- BREA
- Analyst Count
- AIM 2
- BREA 0
- Target Price
- AIM $2.75
- BREA N/A
- AVG Volume (30 Days)
- AIM 672.1K
- BREA 1.3M
- Earning Date
- AIM 11-15-2024
- BREA 01-03-2025
- Dividend Yield
- AIM N/A
- BREA N/A
- EPS Growth
- AIM N/A
- BREA N/A
- EPS
- AIM N/A
- BREA N/A
- Revenue
- AIM $190,000.00
- BREA $2,872,101.00
- Revenue This Year
- AIM N/A
- BREA N/A
- Revenue Next Year
- AIM $1,693.10
- BREA N/A
- P/E Ratio
- AIM N/A
- BREA N/A
- Revenue Growth
- AIM N/A
- BREA 2338.69
- 52 Week Low
- AIM $0.16
- BREA $0.50
- 52 Week High
- AIM $0.62
- BREA $3.00
- Technical
- Relative Strength Index (RSI)
- AIM 50.86
- BREA 51.27
- Support Level
- AIM $0.19
- BREA $0.71
- Resistance Level
- AIM $0.23
- BREA $0.82
- Average True Range (ATR)
- AIM 0.02
- BREA 0.13
- MACD
- AIM -0.00
- BREA -0.00
- Stochastic Oscillator
- AIM 48.29
- BREA 14.61
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.